Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | Director | April 03, 2017 | April 05, 2017 |
| INCYTE CORPINCY · Entity 3182 | Director | May 26, 2020 | May 28, 2020 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | January 09, 2026 | January 13, 2026 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,819 |
Reported balance
After 2017-04-03 transaction · row 1
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 10,273 · Balance 18,819 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017.
INCYTE CORP
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 256,813 |
Reported balance
After 2020-05-26 transaction · row 1
1 source rowRow 1 · 2020-05-26 · Grant · Acquired 1,282 · Balance 256,813 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.68 · Expires 2030-05-25 | Direct | 10,514 |
Reported balance
After 2020-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-26 · Grant · Acquired 10,514 · Balance 10,514 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
| Common StockSEC Table I · non-derivative | IndirectBy Grat | 15,000 |
Reported balance
Holding disclosure · report date 2020-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
MADRIGAL PHARMACEUTICALS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,164 |
Ending reported balance
After 2026-01-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-09 · Exercise / conversion · Acquired 280 · Balance 187,444 Row 2 · 2026-01-09 · Sale · Disposed 280 · Balance 187,164 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.80 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-09 · Exercise / conversion · Disposed 280 · Balance 0 F4: The shares underlying this stock option are fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy SQN LLC | 655,540 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 655,540 F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: The shares underlying this stock option are fully vested and exercisable.
Prelude Therapeutics Inc
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08 | Direct | 38,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 12,840 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2020 Filed Sep 30, 2020 23:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionCommon Stock | 295,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052518 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:27 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,514 | $0.00 Strike: $98.68 | $0.00 |
DisclosureSEC source: 0001209191-20-032596 · doc4.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:27 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032596 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,813 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| May 14, 2020 Filed May 18, 2020 17:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 3,468 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000044 · wf-form4_158983632867339.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,345 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the earlier of (i) the first anniversary of the grant date and (ii) the date of the 2021 Annual Shareholder Meeting. Read SEC document |
| March 27, 2020 Filed Sep 30, 2020 23:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseSeries B Preferred Stock · Derivative | 76,288 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052518 · doc4.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,576 Underlying: Common Stock · 76,288 shares Expires not disclosed F2 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock may be automatically converted into one share of the Issuer's Common Stock or, at the lection of the holder and subject to certain conditions, Non-Voting Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Notwithstanding the foregoing, the option to convert into Non-Voting Common Stock shall be limited to no more than 40% of the aggregate shares of common stock issuable to such holder upon conversion of such holder's convertible preferred stock. F3 · shares: The number of securities reported reflects the one-for-1.1566 reverse stock split of the Issuer's common stock and convertible preferred stock that was effected on September 18, 2020. F2 · price: Each share of the Issuer's Series B Preferred Stock may be automatically converted into one share of the Issuer's Common Stock or, at the lection of the holder and subject to certain conditions, Non-Voting Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Notwithstanding the foregoing, the option to convert into Non-Voting Common Stock shall be limited to no more than 40% of the aggregate shares of common stock issuable to such holder upon conversion of such holder's convertible preferred stock. F2 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock may be automatically converted into one share of the Issuer's Common Stock or, at the lection of the holder and subject to certain conditions, Non-Voting Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Notwithstanding the foregoing, the option to convert into Non-Voting Common Stock shall be limited to no more than 40% of the aggregate shares of common stock issuable to such holder upon conversion of such holder's convertible preferred stock. F2 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock may be automatically converted into one share of the Issuer's Common Stock or, at the lection of the holder and subject to certain conditions, Non-Voting Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Notwithstanding the foregoing, the option to convert into Non-Voting Common Stock shall be limited to no more than 40% of the aggregate shares of common stock issuable to such holder upon conversion of such holder's convertible preferred stock. F3 · derivative.underlying: The number of securities reported reflects the one-for-1.1566 reverse stock split of the Issuer's common stock and convertible preferred stock that was effected on September 18, 2020. F3 · derivative.underlying_shares: The number of securities reported reflects the one-for-1.1566 reverse stock split of the Issuer's common stock and convertible preferred stock that was effected on September 18, 2020. F3 · balance_after: The number of securities reported reflects the one-for-1.1566 reverse stock split of the Issuer's common stock and convertible preferred stock that was effected on September 18, 2020. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 22:04 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $91.79 | $0.00 |
DisclosureSEC source: 0000899243-20-007222 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2021) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77,934 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · derivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,934 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 77,934 | $82.20 | $6,406,174.80 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,531 F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $82.00 - $82.68. F3 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 06, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 77,934 | $18.32 | $1,427,750.88 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 22,066 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · derivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,934 Underlying: Common Stock · 22,066 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 02, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 22,066 | $84.41 | $1,862,591.06 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,531 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $84 - $84.92. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 02, 2019 Filed Aug 6, 2019 22:45 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 22,066 | $18.32 | $404,249.12 |
DisclosureSEC source: 0001209191-19-044887 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:31 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000068 · wf-form4_155812509995850.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,472 | $0.00 Strike: $75.03 | $0.00 |
DisclosureSEC source: 0001209191-19-026442 · doc4.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Underlying: Common Stock · 12,472 shares Expires 2029-04-25 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026442 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,531 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $127.96 | $0.00 |
DisclosureSEC source: 0000899243-19-007018 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 7, 2020) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 20, 2018 Filed Nov 24, 2018 01:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 4,000 | $117.88 | $471,520.00 |
DisclosureSEC source: 0001179110-18-013140 · edgar.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,128 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.39 to $118.11, inclusive. The reporting person undertakes to provide to Madrigal Pharmaceuticals, Inc., any security holder of Madrigal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 19, 2018 Filed Nov 19, 2018 23:26 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | PurchaseCommon Stock | 4,000 | $124.00 | $496,000.00 |
DisclosureSEC source: 0001179110-18-013019 · edgar.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,128 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:56 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 73,526 | $287.46 | $21,135,783.96 |
DisclosureSEC source: 0001179110-18-008428 · edgar.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By SQN LLC Disclosed balance after: 655,540 F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 09, 2018 Filed May 11, 2018 16:10 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000089 · wf-form4_152606936697401.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,151 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:36 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $60.85 | $0.00 |
DisclosureSEC source: 0001209191-18-027769 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $124.45 | $0.00 |
DisclosureSEC source: 0001179110-18-003405 · edgar.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2019) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 16:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,977 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000182 · wf-form4_151207636212265.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,977 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 21:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 28,507 | $105.24 | $3,000,076.68 |
DisclosureSEC source: 0001209191-17-061769 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,011 F1 · price: The reporting person contributed Incyte Common Stock on November 16, 2017 to an exchange fund in exchange for limited partnership units of the exchange fund. The Incyte Common Stock was valued at $105.24 per share for the purpose of determining the number of limited partnership units of the exchange fund issuable to the reporting person. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:33 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $134.38 | $0.00 |
DisclosureSEC source: 0001209191-17-036456 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:33 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 10,273 | $0.73 | $7,499.29 |
DisclosureSEC source: 0001209191-17-025668 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,819 F1 · price: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 41,693 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · derivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 41,693 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 41,693 | $148.18 | $6,178,068.74 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,518 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $148.00 - $148.92. Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 41,693 | $18.32 | $763,815.76 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,849 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · derivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,693 Underlying: Common Stock · 2,849 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,458 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · derivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,458 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 8,307 | $151.45 | $1,258,095.15 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,518 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $151.09 - $151.75. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,849 | $18.32 | $52,193.68 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:10 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 5,458 | $18.32 | $99,990.56 |
DisclosureSEC source: 0001209191-17-021699 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 20:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 49,600 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001179110-17-003949 · edgar.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,600 Underlying: Common Stock · 49,600 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 2, 2018) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 21:54 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-17-014829 · doc4.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,542 Underlying: Common Stock · 50,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 21:54 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 50,000 | $120.32 | $6,016,000.00 |
DisclosureSEC source: 0001209191-17-014829 · doc4.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,518 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $120.00 - $120.64. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 21:54 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 50,000 | $18.32 | $916,000.00 |
DisclosureSEC source: 0001209191-17-014829 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:20 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 4,870 | $0.77 | $3,749.90 |
DisclosureSEC source: 0001209191-17-002055 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,546 F1 · price: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017. Read SEC document |
| October 03, 2016 Filed Oct 20, 2016 22:57 UTC | Dare Bioscience, Inc. CERU · Entity 7799 | GrantCommon Stock | 3,676 | $1.02 | $3,749.52 |
DisclosureSEC source: 0001209191-16-146520 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 F1 · shares: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the third fiscal quarter of 2016 divided by $1.02, the closing price of the company's common stock on the NASDAQ Global Market on October 3, 2016. F1 · price: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the third fiscal quarter of 2016 divided by $1.02, the closing price of the company's common stock on the NASDAQ Global Market on October 3, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.